SCHEMBL4018903

SCHEMBL4018903

CCOC(=O)c1ncc(F)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.43
JMJD6 Q6NYC1 1/20 0.43
NPC1 O15118 2/20 0.43
LMNA P02545 1/20 0.43
RAB9A P51151 1/20 0.43
AGBL2 Q5U5Z8 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
TSHR P16473 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
XBP1 P17861 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TLR9 Q9NR96 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29664441 1.00 THRB (0.43) THRBJMJD6NPC1LMNARAB9A
SCHEMBL20399682 0.87 JMJD6 (0.43) JMJD6NPC1LMNARAB9ACYP2C9
SCHEMBL30697102 0.87 JMJD6 (0.43) JMJD6NPC1LMNARAB9ACYP2C9
SCHEMBL15968597 0.85 CA12 (0.46) JMJD6NPC1LMNARAB9ACYP2C9
SCHEMBL18394836 0.84 NPC1 (0.49) NPC1LMNARAB9AAGBL2CYP2C9
SCHEMBL17362538 0.84 TARBP2 (0.42) JMJD6NPC1RAB9ACYP2C9CYP2C19
SCHEMBL7684716 0.84 S1PR1 (0.49) JMJD6NPC1LMNARAB9ACYP2C9
SCHEMBL25780807 0.83 GABRA1 (0.43) JMJD6NPC1LMNARAB9AAGBL2
SCHEMBL29050073 0.81 KDM4E (0.41) THRBNPC1LMNARAB9AAGBL2
SCHEMBL30405953 0.81 KDM4E (0.41) THRBNPC1LMNARAB9AAGBL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12616696-B2 Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one ACLARIS THERAPEUTICS, INC. (US) 2026-05-05 US disclosed
US-12545662-B2 MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2026-02-10 US disclosed
US-12384757-B2 Methods of synthesizing substituted pyridinone-pyridinyl compounds ACLARIS THERAPEUTICS, INC. (US) 2025-08-12 US disclosed
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-05-13 US disclosed
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-04-08 US disclosed
CN-119528804-A 2- { [2- (Phenoxymethyl) pyridin-5-yl ] oxy } ethanamine derivatives and related compounds as pest control agents, for example, for protecting plants 发现号收购集团 2025-02-28 CN disclosed
CN-119454711-A Methods, compositions and crystalline forms of substituted pyridone-pyridinyl compounds 阿克拉瑞斯治疗股份有限公司 2025-02-18 CN disclosed
CN-119285538-A 2- { [2- (Phenoxymethyl) pyridin-5-yl ] oxy } ethanamine derivatives and related compounds as pest control agents, for example, for protecting plants 发现号收购集团 2025-01-10 CN disclosed
CN-119176794-A Heterocyclic compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-12-24 CN disclosed
CN-119053588-A P38 alpha-MK 2 inhibitor compound, pharmaceutical composition and application thereof 长春金赛药业有限责任公司 2024-11-29 CN disclosed
US-20140364442-A1 METHYL/FLUORO-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS AND FLUORO-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS ACLARIS THERAPEUTICS, INC. 2014-12-11 US disclosed
US-20140364442-A1 METHYL/FLUORO-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS AND FLUORO-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS ACLARIS THERAPEUTICS, INC. 2014-12-11 US disclosed
US-20140364442-A1 METHYL/FLUORO-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS AND FLUORO-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS ACLARIS THERAPEUTICS, INC. 2014-12-11 US disclosed
WO-2013086208-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS CONFLUENCE LIFE SCIENCES, INC. (US) 2013-06-13 WO disclosed
WO-2013086208-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS CONFLUENCE LIFE SCIENCES, INC. (US) 2013-06-13 WO disclosed
US-20130143906-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS CONFLUENCE LIFE SCIENCES, INC. (US) 2013-06-06 US disclosed
US-20130143906-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS CONFLUENCE LIFE SCIENCES, INC. (US) 2013-06-06 US disclosed
US-20130143906-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS CONFLUENCE LIFE SCIENCES, INC. (US) 2013-06-06 US disclosed
WO-2009095712-A2 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2009-08-06 WO disclosed
WO-2008117050-A1 PYRAZOLYL-AMINO-SUBSTITUTED PYRAZINES AND THEIR USE FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384757-B2 Methods of synthesizing substituted pyridinone-pyridinyl compounds PIR, PUM1, ZRANB2 THRB 4614/4885JMJD6 915/4885NPC1 1396/4885
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 THRB 1945/4885JMJD6 3008/4885NPC1 224/4885
US-20130143906-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS MAP3K8, MAP3K1, MAP3K2 THRB 1435/4885JMJD6 1433/4885NPC1 1629/4885
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ACE, ACE2, SPCS3 THRB 4643/4885JMJD6 3668/4885NPC1 399/4885
US-12616696-B2 Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one MALT1, SSB, BCL9 THRB 2992/4885JMJD6 1462/4885NPC1 1228/4885
US-12545662-B2 MK2 inhibitors and uses thereof NR3C2, NR2C2, AGTR2 THRB 1037/4885JMJD6 811/4885NPC1 1460/4885
US-20140364442-A1 METHYL/FLUORO-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS AND FLUORO-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS MAPK1, MAP3K1, MAPK6 THRB 1952/4885JMJD6 261/4885NPC1 4276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.